Rockefeller Capital Management
RGC icon

Rockefeller Capital Management’s Regencell Bioscience RGC Stock Holding History

Rockefeller Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509 Sell
20
-55
-73% -$1.56K ﹤0.01% 4562
2025
Q4 		$1.57K Buy
+75
New +$1.22K ﹤0.01% 4372

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Rockefeller Capital Management's RGC Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Regencell Bioscience (RGC) stake by 73% in Q1 2026, selling an estimated $1.56K and leaving 20 shares worth $509. The position accounts for ﹤0.01% of the portfolio, ranked #4562.

Rockefeller Capital Management first reported a position in RGC in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.57K in Q4 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Rockefeller Capital Management held 20 shares of Regencell Bioscience worth $509 as of Q1 2026.
  • Rockefeller Capital Management sold 55 Regencell Bioscience shares in Q1 2026, an estimated $1.56K.
  • Regencell Bioscience made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4562 holding.
  • Rockefeller Capital Management first reported a position in Regencell Bioscience in Q4 2025 and has held it in 2 quarters since.
  • Rockefeller Capital Management's Regencell Bioscience position peaked at $1.57K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.